Pacifico Biolabs announced that it has raised €7 million in Series A funding to accelerate the scale-up of its mycelium protein production platform and support the company’s commercial launch strategy. The financing marks a significant milestone for the Berlin-based food technology startup as it seeks to expand manufacturing capacity and strengthen its position within the rapidly growing alternative protein market.
Founded to address the increasing demand for sustainable and resource-efficient food production, Pacifico Biolabs develops protein products derived from mycelium, the root-like structure of fungi. The company utilizes a fermentation-based process designed to produce high-quality protein ingredients while reducing the environmental footprint associated with traditional animal agriculture. By leveraging biotechnology and existing industrial infrastructure, Pacifico Biolabs aims to create scalable protein solutions that can meet future global food needs.
The company said the newly secured capital will be used to expand production capabilities through its proprietary fermentation platform, which is designed to operate within existing brewery facilities. Rather than building entirely new manufacturing plants, Pacifico Biolabs partners with breweries that have available fermentation capacity, enabling the company to utilize underused industrial assets and accelerate deployment. Management believes this model can significantly reduce capital expenditures while shortening the timeline required to bring sustainable protein products to market.
The Series A round attracted support from a group of investors focused on food innovation, sustainability, and biotechnology. Participants in the financing included Stray Dog Capital, TGFS Technologiegründerfonds Sachsen, Sprout & About Ventures, Simon Capital, FoodLabs, and a regional brewery partner. The investor syndicate reflects growing interest in technologies that can improve food system resilience while addressing environmental and supply chain challenges.
Pacifico Biolabs noted that the funding will support several strategic initiatives during the company’s next phase of growth. In addition to increasing production capacity, the company plans to expand its workforce, strengthen research and development efforts, and advance commercialization activities across key European markets. The company also intends to continue refining its fermentation technology and supply chain operations as it prepares for broader market adoption.
The company’s production strategy is centered on the belief that existing fermentation infrastructure can play a critical role in scaling alternative proteins more efficiently. By integrating biotechnology with established industrial facilities, Pacifico Biolabs aims to create a flexible manufacturing network capable of supporting future growth without requiring significant new construction. The approach also provides breweries with opportunities to generate additional value from existing assets amid changing market dynamics.
Looking ahead, Pacifico Biolabs plans to bring its mycelium-based protein products to retail shelves by late 2026. The company believes its technology can help deliver nutritious, sustainable protein options to consumers while supporting broader efforts to reduce the environmental impact of food production.
The announcement underscores Pacifico Biolabs’ commitment to combining European industrial infrastructure with biotechnology innovation as it works to develop the next generation of protein products and contribute to the evolution of the global food system.
